Innovative Medicine

Innovative Medicine

October 28, 2013

New Two-Year Results Show SIMPONI® ARIA™ (GOLIMUMAB) For Infusion Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis

Nearly 70 Percent of Patients Receiving SIMPONI ARIA at Two Years Demonstrated ACR 20 Response

Innovative Medicine

October 24, 2013

FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients

Innovative Medicine

October 15, 2013

Janssen Submits Marketing Authorisation Application to European Medicines Agency for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat

Innovative Medicine

October 8, 2013

Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GlaxoSmithKline

Innovative Medicine

October 7, 2013

Simeprevir Data from COSMOS study in Hepatitis C Patients Accepted as Late-Breaking Presentation at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Innovative Medicine

October 1, 2013

Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Innovative Medicine

September 30, 2013

New Study Shows Circulating Tumor Cell Enumeration – as Part of Composite Biomarker Panel –May Serve as a Surrogate for Efficacy Response in Metastatic Castration-Resistant Prostate Cancer

First study to find patients with unfavorable risk profile at 12 weeks have worse prognosis and should be considered for alternative treatments

Innovative Medicine

September 27, 2013

Japanese Health Authority Approves SOVRIAD™ For The Treatment Of Genotype-1 Chronic HCV Infection

Japan is the first country in the world where SOVRIAD™ is approved

Research

September 25, 2013

Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention